药物共付代金券对心肌梗死患者P2Y12抑制剂使用及主要不良心血管事件的影响:ARTEMIS随机临床试验
ARTEMIS集群随机临床试验纳入301家医院的11001例急性心肌梗死成人患者,干预组131家医院(6436例)提供氯吡格雷或替格瑞洛共付代金券1年,常规护理组156家医院(4565例)不提供。1年时患者报告的P2Y12抑制剂持续使用率干预组87.0% vs 对照组83.8%(调整差值2.3%,95%CI 0.4%至4.1%;调整OR 1.19,95%CI 1.02至1.40)。1年MACE累积发生率干预组10.2% vs 对照组10.6%(调整差值0.66%,95%CI -0.73%至2.06%;调整HR 1.07,95%CI 0.93至1.25),无显著差异。
要点
- 在急性心肌梗死出院带氯吡格雷或替格瑞洛处方患者中,提供共付代金券使1年患者报告持续使用率从83.8%升至87.0%(调整差值2.3%,95%CI 0.4%至4.1%)。
- 共付代金券未显著降低1年MACE(死亡、再发心梗或卒中):干预组10.2% vs 对照组10.6%(调整HR 1.07,95%CI 0.93至1.25)。
- 干预组6135例中4393例(72%)使用了代金券,30天供应量代金券中位面值137美元(25th-75th百分位20-339美元)。
- 干预组氯吡格雷处方比例36.0%,常规护理组54.7%,P2Y12抑制剂选择由临床医生自行决定。
适用人群与场景
- 成人急性心肌梗死患者,2015年6月5日至2016年9月30日入组,出院时带氯吡格雷或替格瑞洛处方,随访1年(末次随访2017年10月23日)。
处置流程与药物剂量
- 干预组医院向患者提供氯吡格雷或替格瑞洛共付代金券1年,30天供应量代金券中位面值137美元(25th-75th百分位20-339美元)。
- 常规护理组医院不提供研究代金券。
- P2Y12抑制剂选择由临床医生自行决定。
研究设计与关键结果
- 集群随机临床试验,301家医院,11001例患者(中位年龄62岁,女性3459例[31%]),10102例出院带氯吡格雷或替格瑞洛处方;干预组131家医院6436例,常规护理组156家医院4565例。
- 1年患者报告P2Y12抑制剂持续使用率(定义为无≥30天治疗缺口)干预组5340/6135(87.0%)vs 对照组3324/3967(83.8%),P<.001;调整差值2.3%(95%CI 0.4%至4.1%),调整OR 1.19(95%CI 1.02至1.40)。
- 1年MACE(死亡、再发心梗或卒中)未调整累积发生率干预组10.2% vs 对照组10.6%,P=.65;调整差值0.66%(95%CI -0.73%至2.06%),调整HR 1.07(95%CI 0.93至1.25),无显著差异。
- 干预组6135例中4393例(72%)使用了代金券;1年随访数据可得10802例(98.2%)。
- 氯吡格雷处方比例:干预组2317/6436(36.0%)vs 常规护理组2497/4565(54.7%)。
证据类型、等级与局限
- 证据类型:集群随机临床试验(ARTEMIS),ClinicalTrials.gov注册号NCT02406677。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在心肌梗死患者中提供共付代金券以抵消P2Y12抑制剂共付费用,与不提供代金券相比,可使患者报告的P2Y12抑制剂持续使用率绝对增加3.3%,但未显著降低1年MACE。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardial infarction (MI), and higher-potency P2Y12 inhibitors are underutilized. Cost is frequently cited as an explanation for both of these observations.
OBJECTIVE: To determine whether removing co-payment barriers increases P2Y12 inhibitor persistence and lowers risk of major adverse cardiovascular events (MACE).
DESIGN, SETTING, AND PARTICIPANTS: Cluster randomized clinical trial among 301 hospitals enrolling adult patients with acute MI (June 5, 2015, through September 30, 2016); patients were followed up for 1 year after discharge (final date of follow-up was October 23, 2017), with blinded adjudication of MACE; choice of P2Y12 inhibitor was per clinician discretion.
INTERVENTIONS: Hospitals randomized to the intervention (n = 131 [6436 patients]) provided patients with co-payment vouchers for clopidogrel or ticagrelor for 1 year (median voucher value for a 30-day supply, $137 [25th-75th percentile, $20-$339]). Hospitals randomized to usual care (n = 156 [4565 patients]) did not provide study vouchers.
MAIN OUTCOMES AND MEASURES: Independent coprimary outcomes were patient-reported persistence with P2Y12 inhibitor (defined as continued treatment without gap in use ≥30 days) and MACE (death, recurrent MI, or stroke) at 1 year among patients discharged with a prescription for clopidogrel or ticagrelor.
RESULTS: Among 11 001 enrolled patients (median age, 62 years; 3459 [31%] women), 10 102 patients were discharged with prescriptions for clopidogrel or ticagrelor (clopidogrel prescribed to 2317 [36.0%] in the intervention group and 2497 [54.7%] in the usual care group), 4393 of 6135 patients (72%) in the intervention group used the voucher, and follow-up data at 1 year were available for 10 802 patients (98.2%). Patient-reported persistence with P2Y12 inhibitors at 1 year was higher in the intervention group than in the control group (unadjusted rates, 5340/6135 [87.0%] vs 3324/3967 [83.8%], respectively; P < .001; adjusted difference, 2.3% [95% CI, 0.4% to 4.1%]; adjusted odds ratio, 1.19 [95% CI, 1.02 to 1.40]). There was no significant difference in MACE at 1 year between intervention and usual care groups (unadjusted cumulative incidence, 10.2% vs 10.6%; P = .65; adjusted difference, 0.66% [95% CI, -0.73% to 2.06%]; adjusted hazard ratio, 1.07 [95% CI, 0.93 to 1.25]).
CONCLUSIONS AND RELEVANCE: Among patients with MI, provision of vouchers to offset medication co-payments for P2Y12 inhibitors, compared with no vouchers, resulted in a 3.3% absolute increase in patient-reported persistence with P2Y12 inhibitors and no significant reduction in 1-year MACE outcomes.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02406677.
参考来源
- Wang TY, Kaltenbach LA, Cannon CP, et al. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. JAMA. 2019. PMID: 30620370. doi:10.1001/jama.2018.19791
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。